Schering-Plough (SGP): Select Joint Ventures, Partnerships, and Alliances
Friday, 07 September 2007
Friday, 07 September 2007
Cite as Judit Rius Sanjuan, James Love and Robert Weissman, Protection of Pharmaceutical Test Data: A Policy Proposal, KEI Research Paper 2006:1.
PROTECTION OF PHARMACEUTICAL TEST DATA: A POLICY
PROPOSAL*1
Judit Rius Sanjuan, James Love and Robert Weissman*2
KEI Research Paper 2006:1
21 November 2006
KEI Research Note 2007:2 [1]
(A PDF version of this is available here.)
KEI Research Note 2007:2
$1 a day HIV/AIDS drug regimen
In the early 2000s, KEI’s founder, James Love, advocated to lower the price of HIV/AIDS drugs for patients in developing countries. Love convinced generic manufacturer Cipla to sell the standard 3-drug HIV/AIDS regimen for $1 per day, a breakthrough price that saved — and continues to save — millions of lives. Love’s work culminated in the creation of the Global Fund for HIV/AIDS, TB and Malaria and the President’s Emergency Plan For AIDS Relief (PEPFAR), two of the world’s largest providers of HIV/AIDS treatments.
UNITAID patent pool for medicines
Cost Benefit Analysis for UNITAID Patent Pool
UNITAIDwebsite on patent pools
MSF website on patent pools
KEI will host a meeting on the Bilski litigation regarding patents on business methods, on September 10, 2009, from noon to 2:00.
When: Thursday, September 10, 2009 Time: 12:00-2:00pm Location: Knowledge Ecology International (KEI) 1621 Connecticut Ave NW, Suite 500 Washington, DC 20009 Tel +1 202 332 2670The meeting will include presentations by:
James Love and James K. Glassman, Don’t Kill Competition for High-Tech Drugs, Roll Call, Sept. 9, 2009.
KEI Statement on Eshoo/Barton amendment
Some reporting
In May 2009, at the WIPO Standing Committee on Copyright and Related Rights (SCCR) 18th session, the governments of Brazil, Ecuador and Paraguay formally tabled a proposal to WIPO endorsing the World Blind Union’s Treaty for Reading Disabled Persons.
In an August 14, 2009 article in the LA Times, Tom Hamburger provides yet another installment in the ongoing disclosures about a secret White House deal with PhRMA on pharmaceutical pricing.